Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework

Louis P Garrison; Jeroen Jansen; Nancy Devlin; Susan Griffin

doi:10.1016/j.jval.2019.04.1915

Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework

Louis P Garrison, Jeroen Jansen, Nancy Devlin, Susan Griffin

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis (CEA) of healthcare interventions based on the cost-per-quality-adjusted life-year (QALY) metric by incorporating into health technology assessment (HTA) additional elements that create value for patients and society. Louis Garrison began the session by providing an overview of the recommendations of the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR’s) Special Task Force (STF) on value frameworks. Jeroen Jansen presented his thoughts on how value assessment might move beyond conventional CEA, introducing the need to acknowledge patient diversity. Nancy Devlin discussed approaches that may be taken to extend the scope of patient-reported outcomes (PROs) and quality of life. And finally, Susan Griffin discussed the use of distributional CEA to capture the value of reducing inequality in health.

Original language	English
Pages (from-to)	S12-S17
Number of pages	6
Journal	Value in Health
Volume	22
Issue number	6
DOIs	https://doi.org/10.1016/j.jval.2019.04.1915
Publication status	Published - 12 Jun 2019

Access to Document

10.1016/j.jval.2019.04.1915

DoH PRP: PHRC - Identifying appropriate methods to incorporate concerns about health inequalities into economic evaluations of health care programme
Sculpher, M., Asaria, M., Asaria, M., Cookson, R. A., Cookson, R. A., Griffin, S. & Griffin, S.
1/04/11 → 31/03/16
Project: Research project (funded) › Research

Cite this

@article{d782a5fafc8b42fc91e4f06ebd8e32a6,

title = "Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework",

abstract = "The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis (CEA) of healthcare interventions based on the cost-per-quality-adjusted life-year (QALY) metric by incorporating into health technology assessment (HTA) additional elements that create value for patients and society. Louis Garrison began the session by providing an overview of the recommendations of the International Society for Pharmacoeconomics and Outcomes Research{\textquoteright}s (ISPOR{\textquoteright}s) Special Task Force (STF) on value frameworks. Jeroen Jansen presented his thoughts on how value assessment might move beyond conventional CEA, introducing the need to acknowledge patient diversity. Nancy Devlin discussed approaches that may be taken to extend the scope of patient-reported outcomes (PROs) and quality of life. And finally, Susan Griffin discussed the use of distributional CEA to capture the value of reducing inequality in health.",

author = "Garrison, {Louis P} and Jeroen Jansen and Nancy Devlin and Susan Griffin",

year = "2019",

month = jun,

day = "12",

doi = "10.1016/j.jval.2019.04.1915",

language = "English",

volume = "22",

pages = "S12--S17",

journal = "Value in Health",

issn = "1098-3015",

publisher = "Elsevier",

number = "6",

}

TY - JOUR

T1 - Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework

AU - Garrison, Louis P

AU - Jansen, Jeroen

AU - Devlin, Nancy

AU - Griffin, Susan

PY - 2019/6/12

Y1 - 2019/6/12

N2 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis (CEA) of healthcare interventions based on the cost-per-quality-adjusted life-year (QALY) metric by incorporating into health technology assessment (HTA) additional elements that create value for patients and society. Louis Garrison began the session by providing an overview of the recommendations of the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR’s) Special Task Force (STF) on value frameworks. Jeroen Jansen presented his thoughts on how value assessment might move beyond conventional CEA, introducing the need to acknowledge patient diversity. Nancy Devlin discussed approaches that may be taken to extend the scope of patient-reported outcomes (PROs) and quality of life. And finally, Susan Griffin discussed the use of distributional CEA to capture the value of reducing inequality in health.

AB - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis (CEA) of healthcare interventions based on the cost-per-quality-adjusted life-year (QALY) metric by incorporating into health technology assessment (HTA) additional elements that create value for patients and society. Louis Garrison began the session by providing an overview of the recommendations of the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR’s) Special Task Force (STF) on value frameworks. Jeroen Jansen presented his thoughts on how value assessment might move beyond conventional CEA, introducing the need to acknowledge patient diversity. Nancy Devlin discussed approaches that may be taken to extend the scope of patient-reported outcomes (PROs) and quality of life. And finally, Susan Griffin discussed the use of distributional CEA to capture the value of reducing inequality in health.

U2 - 10.1016/j.jval.2019.04.1915

DO - 10.1016/j.jval.2019.04.1915

M3 - Article

SN - 1098-3015

VL - 22

SP - S12-S17

JO - Value in Health

JF - Value in Health

IS - 6

ER -

Novel Approaches to Value Assessment Within the Cost-Effectiveness Framework

Abstract

Access to Document

Projects

DoH PRP: PHRC - Identifying appropriate methods to incorporate concerns about health inequalities into economic evaluations of health care programme

Cite this